<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>phenylalanine metabolism predicts nCRT therapeutic response in rectal cancer — pCite</title>
<link rel="stylesheet" href="../css/style.css">
</head>
<body>
<header>
  <h1><a href="../index.html">pCite</a></h1>
  <nav><a href="../index.html">Search</a><a href="../corpus.html">Corpus</a></nav>
</header>

<p class="section-label">CLAIM</p>
<hr class="section-rule">
<div class="triple">
  <strong>phenylalanine metabolism</strong>
  <span class="pred">&mdash;predicts&rarr;</span>
  <strong>nCRT therapeutic response in rectal cancer</strong>
</div>
<div class="entity-id">UNKNOWN:phenylalanine metabolism &nbsp;&middot;&nbsp; MESH:D012004</div>

<p class="section-label">VALIDATION</p>
<hr class="section-rule">
<div class="val-bar" style="--pct:5%;--color:#f0a030"></div>
<div class="stat-row">
  <span>Class: DB Referenced (0.5)</span>
  <span>Replicated: 1 paper</span>
  <span>Score: 1.47<span class="score-tip"><span class="tip-icon">&nbsp;&#9432;</span><span class="tip-text">Score = &Sigma; incoming citation weights. Each citation is weighted by the validation class of the source claim (Physical 10.0 &middot; DB Ref 0.5 &middot; Text Derived 0.01) multiplied by the citation type (Replicates 1.5 &middot; Supports 1.0 &middot; Contradicts &minus;0.5). A score of 364 means this claim received strong physical-tier citation support.</span></span></span>
</div>

<p class="section-label">SCORE BREAKDOWN</p>
<hr class="section-rule">
<div class="score-breakdown">Base weight: 0.50 (DB Referenced, 1 paper)<br>Score from 31 citations: <strong>1.47</strong><br><span style="color:#888">21&times; extends (+1.43) &middot; 6&times; supports (+1.04) &middot; 4&times; contradicts (-1.00)</span><br>Neighbourhood: 4.19</div>


<p class="section-label">EVIDENCE CHAIN &middot; 1 source</p>
<hr class="section-rule">
<div class="evidence-row"><span class="evidence-dot" style="background:#f0a030" title="DB Referenced"></span><span>DB Referenced</span><a href="https://doi.org/10.1038/s41467-022-35511-y">10.1038/s41467-022-35511-y</a></div>


<p class="section-label">CITATIONS RECEIVED &middot; 31 total</p>
<hr class="section-rule">
<div class="cite-bar"><span style="width:70px;text-align:right">Replicates</span><span class="cite-bar-fill" style="width:0px"></span><span>0</span></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Supports</span><span class="cite-bar-fill" style="width:29px"></span><span>6</span><span class="cite-subtotal">&middot; +1.04</span></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Serum metabolite profile — distinguishes → Pathological complete response vs non-complete response in rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/7a0b9a62ccfe460a.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">L-Tryptophan — decreases → neoadjuvant chemoradiotherapy response in locally advanced rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/0ff9b2690bbd064a.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#f0a030"></span><span class="cite-claim-triple">N-acetyl-L-methionine — correlates_with → XELOX sensitivity</span><span class="cite-claim-weight">+0.50</span><a href="../claim/5d05cec20379fbcc.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#f0a030"></span><span class="cite-claim-triple">Serum metabolite combination (D-glucose 6-phosphate, presqualene diphosphate, leukotriene B4, 15-HETE, N-acetyl-L-methionine) — predicts → XELOX chemotherapeutic efficacy in colorectal cancer</span><span class="cite-claim-weight">+0.50</span><a href="../claim/394c172c9a703d95.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">adipose tissue glutamine — decreases → advanced stage rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/7896c61b911bbef2.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">adipose tissue succinate — increases → advanced stage rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/fd67c830f88881d3.html">view &rarr;</a></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Contradicts</span><span class="cite-bar-fill" style="width:19px"></span><span>4</span><span class="cite-subtotal">&middot; -1.00</span></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#f0a030"></span><span class="cite-claim-triple">D-glucose 6-phosphate — correlates_with → XELOX sensitivity</span><span class="cite-claim-weight">-0.25</span><a href="../claim/7d0504ce53d5569e.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#f0a030"></span><span class="cite-claim-triple">presqualene diphosphate — correlates_with → XELOX sensitivity</span><span class="cite-claim-weight">-0.25</span><a href="../claim/8af9fa7e3ef2d2af.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#f0a030"></span><span class="cite-claim-triple">leukotriene B4 — correlates_with → XELOX sensitivity</span><span class="cite-claim-weight">-0.25</span><a href="../claim/1c5ed45efa0fc550.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#f0a030"></span><span class="cite-claim-triple">15-HETE — correlates_with → XELOX sensitivity</span><span class="cite-claim-weight">-0.25</span><a href="../claim/172099cc6dbba039.html">view &rarr;</a></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Extends</span><span class="cite-bar-fill" style="width:100px"></span><span>21</span><span class="cite-subtotal">&middot; +1.43</span></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Phenylalanine — decreases → neoadjuvant chemoradiotherapy in locally advanced rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/2e2036fffa3b9ca9.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Lysophosphatidylcholine (LysoPC) — correlates_with → pathological complete response in rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/b7622968ba9bd9a4.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Sphingomyelin — correlates_with → pathological complete response in rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/1455190d9b82dc43.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Serum metabolite profile — predicts → pathological complete response in locally advanced rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/fe92c2071c40d0aa.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Chemoradiotherapy — treats → locally advanced rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/b448f30106f59051.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#f0a030"></span><span class="cite-claim-triple">Serum metabolites (unsupervised clustering) — distinguishes → colorectal cancer</span><span class="cite-claim-weight">+0.60</span><a href="../claim/ca0c3cffc9fb77fa.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#f0a030"></span><span class="cite-claim-triple">Cluster 3 (uniform lipid and amino acid levels) — predicts → colorectal cancer prognosis</span><span class="cite-claim-weight">+0.60</span><a href="../claim/2c6033008b70ea79.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">adipose tissue metabolome — distinguishes → rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/6a58dca60a00dc48.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">adipose tissue metabolome — predicts → tumour invasiveness in rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/48acf1f78ee7116e.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">glutamine — is_biomarker_for → rectal cancer disease stage</span><span class="cite-claim-weight">+0.01</span><a href="../claim/ee7b54ab62786c61.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">glutamate — is_biomarker_for → rectal cancer disease stage</span><span class="cite-claim-weight">+0.01</span><a href="../claim/02bb8f293c05b1db.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">succinate — is_biomarker_for → rectal cancer disease stage</span><span class="cite-claim-weight">+0.01</span><a href="../claim/9c5697eb2b7ee5d6.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">fumarate — is_biomarker_for → rectal cancer disease stage</span><span class="cite-claim-weight">+0.01</span><a href="../claim/82051bf9a0591e3c.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">citrate — is_biomarker_for → rectal cancer tumour invasiveness</span><span class="cite-claim-weight">+0.01</span><a href="../claim/df70eeed4675ee99.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">isocitrate — is_biomarker_for → rectal cancer tumour invasiveness</span><span class="cite-claim-weight">+0.01</span><a href="../claim/e1985235e15c5264.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">TCA cycle metabolites — distinguishes → rectal cancer disease stage</span><span class="cite-claim-weight">+0.01</span><a href="../claim/507fb6f59217330c.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">adipose tissue TCA cycle metabolites — predicts → tumour invasiveness in rectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/33d5edd83182d292.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">lysophosphatidylcholines — correlates_with → rectal cancer disease stage</span><span class="cite-claim-weight">+0.01</span><a href="../claim/7eb409c76d4a194c.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">sphingomyelins — correlates_with → rectal cancer disease stage</span><span class="cite-claim-weight">+0.01</span><a href="../claim/4cd692537b16a5ee.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">phosphatidylcholines — correlates_with → rectal cancer tumour invasiveness</span><span class="cite-claim-weight">+0.01</span><a href="../claim/477a53071bd6973c.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">adipose tissue metabolome panel — distinguishes → rectal cancer vs healthy controls</span><span class="cite-claim-weight">+0.01</span><a href="../claim/4ee98e06e3354a23.html">view &rarr;</a></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Applies</span><span class="cite-bar-fill" style="width:0px"></span><span>0</span></div>


<p class="section-label">IDENTIFIERS</p>
<hr class="section-rule">
<table class="id-table">
<tr><td>Claim ID</td><td><code>37cf9aa341c8f61b</code></td></tr>
<tr><td>Subject URI</td><td><a href="https://identifiers.org/UNKNOWN:phenylalanine metabolism">UNKNOWN:phenylalanine metabolism</a></td></tr>
<tr><td>Object URI</td><td><a href="https://identifiers.org/MESH:D012004">MESH:D012004</a></td></tr>
</table>
<footer>pCite — validation-weighted scientific claims</footer>
</body>
</html>
